The natural history of acute hepatitis C: Clinical presentation, laboratory findings and treatment outcomes

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2011, Pages 559-565

  Loomba, R ^a   Rivera, M M ^a   McBurney, R ^b   Park, Y ^a   Haynes Williams, V ^a   Rehermann, B ^a   Alter, H J ^b   Herrine, S K ^c   Liang, T J ^a   Hoofnagle, J H ^a   Heller, T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; JAUNDICE; LABORATORY TEST; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OTITIS MEDIA; PANCREATITIS; PAPILLITIS; PRIORITY JOURNAL; PRURITUS; RHEUMATIC POLYMYALGIA; SIDE EFFECT; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS LOAD; WEIGHT REDUCTION;

ACUTE DISEASE; ADULT; AGED; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251510896     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04549.x     Document Type: Article

References (19)

1. Kim WR,. The burden of hepatitis C in the United States. Hepatology 2002; 36 (Suppl. 1): S30-4.
2. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH,. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 4: 296-305.
3. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL,. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005; 42: 1406-13.
4. Seeff LB, Hoofnagle JH,. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006; 25: 3771-7.
5. Seeff LB, Hoofnagle JH,. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36 (Suppl. 1): S1-2.
6. Alter MJ,. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1: 559-68, vi-vii.
7. Heller T, Rehermann B,. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005; 25: 7-17.
8. Rehermann B, Nascimbeni M,. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
9. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-8.
10. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
11. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-6.
12. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632-8.
13. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 1721-31.
14. Corey KE, Ross AS, Wurcel A, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006; 4: 1278-82.
15. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39: 1213-9.
16. Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004; 40: 87-97.
17. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200: 1216-26.
18. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF,. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol 2010; 22: 157-66.
19. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT,. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17: 201-7.